Influence	O
of	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
on	O
survival	O
in	O
indolent	O
and	O
mantle	O
cell	I:C0334634
lymphomas	I:C0334634
:	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
NHL1	O
trial	O
.	O

Influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
on	O
survival	O
in	O
indolent	B:C1334170
and	O
mantle	O
cell	I:C0334634
lymphomas	I:C0334634
:	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
NHL1	O
trial	O
.	O

Influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
on	O
survival	O
in	O
indolent	O
and	O
mantle	B:C0334634
cell	I:C0334634
lymphomas	I:C0334634
:	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
NHL1	O
trial	O
.	O

Influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
on	O
survival	O
in	O
indolent	O
and	O
mantle	O
cell	I:C0334634
lymphomas	I:C0334634
:	O
analysis	B:C0936012
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
NHL1	O
trial	O
.	O

Influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
on	O
survival	O
in	O
indolent	O
and	O
mantle	O
cell	I:C0334634
lymphomas	I:C0334634
:	O
analysis	O
of	O
the	O
Study	B:C2348561
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
NHL1	O
trial	O
.	O

Influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
on	O
survival	O
in	O
indolent	O
and	O
mantle	O
cell	I:C0334634
lymphomas	I:C0334634
:	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
NHL1	B:C0024305
trial	O
.	O

Obesity	B:C0028754
is	O
a	O
well	O
-	O
known	O
risk	O
factor	I:C0035648
for	O
the	O
development	O
of	O
cancer	O
,	O
but	O
its	O
influence	O
on	O
the	O
course	O
of	O
disease	O
is	O
still	O
controversial	O
.	O

Obesity	O
is	O
a	O
well	O
-	O
known	O
risk	B:C0035648
factor	I:C0035648
for	O
the	O
development	O
of	O
cancer	O
,	O
but	O
its	O
influence	O
on	O
the	O
course	O
of	O
disease	O
is	O
still	O
controversial	O
.	O

Obesity	O
is	O
a	O
well	O
-	O
known	O
risk	O
factor	I:C0035648
for	O
the	O
development	O
of	O
cancer	B:C0006826
,	O
but	O
its	O
influence	O
on	O
the	O
course	O
of	O
disease	O
is	O
still	O
controversial	O
.	O

Obesity	O
is	O
a	O
well	O
-	O
known	O
risk	O
factor	I:C0035648
for	O
the	O
development	O
of	O
cancer	O
,	O
but	O
its	O
influence	O
on	O
the	O
course	O
of	O
disease	B:C0012634
is	O
still	O
controversial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	B:C1334170
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	B:C0334634
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	B:C1515021
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	B:C0936012
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	B:C2348561
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	B:C2348561
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	B:C1334170
Lymphomas	I:C1334170
)	O
NHL1	O
trial	O
.	O

We	O
investigated	O
the	O
influence	O
of	O
body	O
mass	I:C1305855
index	I:C1305855
(	O
body	O
mass	I:C1305855
index	I:C1305855
)	O
on	O
overall	O
survival	O
(	O
OS	O
)	O
in	O
502	O
patients	O
with	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
or	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
in	O
a	O
subgroup	O
analysis	O
of	O
the	O
Study	O
Group	I:C2348561
Indolent	I:C2348561
Lymphomas	I:C2348561
(	O
Study	O
Group	I:C2348561
Indolent	O
Lymphomas	I:C1334170
)	O
NHL1	B:C0024305
trial	O
.	O

We	O
defined	O
a	O
cut	O
-	O
off	O
of	O
22.55	O
kg	O
/	O
m(	O
2	O
)	O
by	O
ROC	O
calculation	O
and	O
Youden	B:C0918012
Index	I:C0918012
analysis	O
and	O
stratified	O
patients	O
into	O
"	O
low	O
BMI	I:C0231255
"	O
and	O
"	O
high	O
BMI	I:C0231254
"	O
.	O

We	O
defined	O
a	O
cut	O
-	O
off	O
of	O
22.55	O
kg	O
/	O
m(	O
2	O
)	O
by	O
ROC	O
calculation	O
and	O
Youden	O
Index	I:C0918012
analysis	B:C0936012
and	O
stratified	O
patients	O
into	O
"	O
low	O
BMI	I:C0231255
"	O
and	O
"	O
high	O
BMI	I:C0231254
"	O
.	O

We	O
defined	O
a	O
cut	O
-	O
off	O
of	O
22.55	O
kg	O
/	O
m(	O
2	O
)	O
by	O
ROC	O
calculation	O
and	O
Youden	O
Index	I:C0918012
analysis	O
and	O
stratified	O
patients	O
into	O
"	O
low	B:C0231255
BMI	I:C0231255
"	O
and	O
"	O
high	O
BMI	I:C0231254
"	O
.	O

We	O
defined	O
a	O
cut	O
-	O
off	O
of	O
22.55	O
kg	O
/	O
m(	O
2	O
)	O
by	O
ROC	O
calculation	O
and	O
Youden	O
Index	I:C0918012
analysis	O
and	O
stratified	O
patients	O
into	O
"	O
low	O
BMI	I:C0231255
"	O
and	O
"	O
high	B:C0231254
BMI	I:C0231254
"	O
.	O

Five	O
-	O
year	O
OS	O
was	O
significantly	O
longer	O
in	O
the	O
high	B:C0231254
BMI	I:C0231254
group	O
(	O
82.2	O
%	O
)	O
when	O
compared	O
to	O
that	O
of	O
the	O
low	O
BMI	I:C0231255
group	O
(	O
66.2	O
%	O
)	O
(	O
HR	O
0.597	O
;	O
95	O
%	O
CI	O
0.370-0.963	O
;	O
p	O
=	O
0.034	O
)	O
.	O

Five	O
-	O
year	O
OS	O
was	O
significantly	O
longer	O
in	O
the	O
high	O
BMI	I:C0231254
group	B:C1257890
(	O
82.2	O
%	O
)	O
when	O
compared	O
to	O
that	O
of	O
the	O
low	O
BMI	I:C0231255
group	O
(	O
66.2	O
%	O
)	O
(	O
HR	O
0.597	O
;	O
95	O
%	O
CI	O
0.370-0.963	O
;	O
p	O
=	O
0.034	O
)	O
.	O

Five	O
-	O
year	O
OS	O
was	O
significantly	O
longer	O
in	O
the	O
high	O
BMI	I:C0231254
group	O
(	O
82.2	O
%	O
)	O
when	O
compared	O
to	O
that	O
of	O
the	O
low	B:C0231255
BMI	I:C0231255
group	O
(	O
66.2	O
%	O
)	O
(	O
HR	O
0.597	O
;	O
95	O
%	O
CI	O
0.370-0.963	O
;	O
p	O
=	O
0.034	O
)	O
.	O

Five	O
-	O
year	O
OS	O
was	O
significantly	O
longer	O
in	O
the	O
high	O
BMI	I:C0231254
group	O
(	O
82.2	O
%	O
)	O
when	O
compared	O
to	O
that	O
of	O
the	O
low	O
BMI	I:C0231255
group	B:C1257890
(	O
66.2	O
%	O
)	O
(	O
HR	O
0.597	O
;	O
95	O
%	O
CI	O
0.370-0.963	O
;	O
p	O
=	O
0.034	O
)	O
.	O

body	B:C1305855
mass	I:C1305855
index	I:C1305855
was	O
also	O
an	O
independent	O
prognostic	O
factor	I:C1514474
for	O
OS	O
in	O
multivariate	O
analysis	O
(	O
HR	O
0.541	O
;	O
95	O
%	O
CI	O
0.332-0.883	O
;	O
p	O
=	O
0.014	O
)	O
.	O

body	O
mass	I:C1305855
index	I:C1305855
was	O
also	O
an	O
independent	O
prognostic	B:C1514474
factor	I:C1514474
for	O
OS	O
in	O
multivariate	O
analysis	O
(	O
HR	O
0.541	O
;	O
95	O
%	O
CI	O
0.332-0.883	O
;	O
p	O
=	O
0.014	O
)	O
.	O

Of	O
note	O
,	O
patients	O
had	O
a	O
significantly	O
lower	B:C0231255
BMI	I:C0231255
in	O
the	O
presence	O
than	O
patients	O
in	O
the	O
absence	O
of	O
B	O
-	I:C1706867
symptoms	I:C1706867
(	O
p	O
=	O
0.025	O
)	O
.	O

Of	O
note	O
,	O
patients	O
had	O
a	O
significantly	O
lower	O
BMI	I:C0231255
in	O
the	O
presence	O
than	O
patients	O
in	O
the	O
absence	O
of	O
B	B:C1706867
-	I:C1706867
symptoms	I:C1706867
(	O
p	O
=	O
0.025	O
)	O
.	O

body	B:C1305855
mass	I:C1305855
index	I:C1305855
significantly	O
impacts	O
on	O
OS	O
in	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
and	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
,	O
which	O
may	O
be	O
influenced	O
by	O
the	O
effect	O
of	O
B	O
-	I:C1706867
symptoms	I:C1706867
on	O
body	O
mass	I:C1305855
index	I:C1305855
.	O

body	O
mass	I:C1305855
index	I:C1305855
significantly	O
impacts	O
on	O
OS	O
in	O
indolent	B:C1334170
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
and	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
,	O
which	O
may	O
be	O
influenced	O
by	O
the	O
effect	O
of	O
B	O
-	I:C1706867
symptoms	I:C1706867
on	O
body	O
mass	I:C1305855
index	I:C1305855
.	O

body	O
mass	I:C1305855
index	I:C1305855
significantly	O
impacts	O
on	O
OS	O
in	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
and	O
mantle	B:C0334634
cell	I:C0334634
lymphoma	I:C0334634
,	O
which	O
may	O
be	O
influenced	O
by	O
the	O
effect	O
of	O
B	O
-	I:C1706867
symptoms	I:C1706867
on	O
body	O
mass	I:C1305855
index	I:C1305855
.	O

body	O
mass	I:C1305855
index	I:C1305855
significantly	O
impacts	O
on	O
OS	O
in	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
and	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
,	O
which	O
may	O
be	O
influenced	O
by	O
the	O
effect	O
of	O
B	B:C1706867
-	I:C1706867
symptoms	I:C1706867
on	O
body	O
mass	I:C1305855
index	I:C1305855
.	O

body	O
mass	I:C1305855
index	I:C1305855
significantly	O
impacts	O
on	O
OS	O
in	O
indolent	O
non-Hodgkin	I:C1334170
's	I:C1334170
lymphoma	I:C1334170
and	O
mantle	O
cell	I:C0334634
lymphoma	I:C0334634
,	O
which	O
may	O
be	O
influenced	O
by	O
the	O
effect	O
of	O
B	O
-	I:C1706867
symptoms	I:C1706867
on	O
body	B:C1305855
mass	I:C1305855
index	I:C1305855
.	O

